Company intelligence / Profile preview

B Banner

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Banner Life Sciences developed BAFIERTAM® (monomethyl fumarate), a disease-modifying therapy for relapsing forms of multiple sclerosis. The product received final FDA approval in 2020 and was commercialized prior to the company's acquisition by Cycle Pharmaceuticals in January 2025. No other clinical results are detailed in the available sources.

Therapeutic areas: Neurology
Modalities: Small molecule (e.g., monomethyl fumarate)
Industry: Biotech

Partnerships

Previously partnered with distribution partners such as Impax and Mylan for certain products before asset sales.

Beyond the preview

Go deeper on B Banner.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B Banner.

Explore the full profile